Sponsors (2)
The bill expands Medicare coverage for guideline‑based genetic testing, high‑risk screening, and preventive cancer surgeries—improving prevention and reducing out‑of‑pocket costs for many beneficiaries—while increasing federal spending and adding administrative complexity that could create regional variation and some access tradeoffs.
Medicare beneficiaries with personal or family histories suspicious for hereditary cancer will gain covered access to guideline-based germline genetic testing, reducing cost barriers to diagnosis and care.
Medicare coverage is explicitly aligned to recognized clinical practice guidelines for testing, screening, and preventive surgeries, promoting more consistent, evidence-based care across providers.
Medicare beneficiaries at high genetic or clinical risk will have preventive, risk‑reducing cancer surgeries covered when guideline‑recommended, lowering future cancer incidence and treatment burden for those individuals.
Expanding Medicare to cover additional genetic testing, more frequent screening, and preventive surgeries will increase Medicare and federal spending, with associated costs to taxpayers and potential budgetary tradeoffs.
Providers and hospitals will face added administrative burden and payment risk to demonstrate that tests, screenings, and surgeries strictly conform to the specified professional guidelines and contractor determinations.
More frequent screening for high‑risk beneficiaries may increase false positives and lead to additional diagnostic procedures, anxiety, and downstream medical costs for some individuals.
Based on analysis of 4 sections of legislative text.
Requires Medicare to cover guideline‑based germline cancer genetic testing, related risk‑reducing surgeries, and more frequent guideline‑aligned screening for mutation carriers.
Introduced September 10, 2025 by Lisa Murkowski · Last progress September 10, 2025
Requires Medicare to cover germline (hereditary) cancer genetic testing for people with a personal or family history or otherwise suspicious for hereditary cancer, and to treat evidence‑based risk‑reducing surgeries as payable under Medicare. Also directs Medicare to relax frequency and other coverage limits for certain cancer screening tests for beneficiaries found to carry a hereditary cancer gene mutation so screening aligns with evidence‑based clinical guidelines; at least annual screening is required.